article thumbnail

Impact of IFM 2009 and DETERMINATION Studies

Pharmacy Times

Panelists discuss how the introduction of triplet therapy prior to transplant in studies like IFM 2009 and DETERMINATION shifted the clinician mindset toward more intensive induction regimens, leading to a focus on achieving deeper responses and longer progression-free survival as primary goals of therapy for newly diagnosed multiple myeloma patients. (..)

Leads 26
article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

While that sounds encouraging, most cancer drugs launched between 2009 and 2014 cost more than USD 100,000 annually. This leads to a question; “where does it end?” COVID-19 has not impacted the number of launches in the oncology space, as 2020 and 2021 have seen similar rates of drug launches as in 2019.

Pharma 210
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

EC approves Novartis’ Tabrecta for non-small cell lung cancer

Pharmaceutical Technology

The treatment is intended for patients with NSCLC harbouring alterations leading to mesenchymal-epithelial-transition factor gene (MET) exon 14 (METex14) skipping and for those who need systemic therapy after previous treatment with immunotherapy and/or platinum-based chemotherapy. It was discovered by Incyte and licensed to Novartis in 2009.

Medicine 105
article thumbnail

Exploring China’s research landscape and its future direction

Clarivate

China has emerged as a leading science and technology power on the global stage, rivaling western nations including the U.S. It shows an acceleration in published research output, which increased five-fold between 2009 and 2021, well outpacing the U.S. Our analysis suggests this trajectory is likely to continue.

article thumbnail

Artificial Intelligence for better antibody drugs: ready for prime time?

pharmaphorum

The process is followed by computationally guided mutagenesis or evolution of the antibody sequence (hit to lead, or H2L, optimisation) to improve the binding and other properties. Consequently, the lead optimisation or molecular evolution offerings in the space are relatively more common among the start-ups. Tours, France.

Biopharma 109
article thumbnail

Innovative Medicines Fund and the opportunity for ICSs to mobilise NICE approvals

pharmaphorum

Nina Pinwill leads the commercial operations function within the Commercial Medicines Directorate at NHS England. Alongside his work as a recognised author, speaker, moderator and industry advisor, he founded the industry-leading publication pharmaphorum in 2009. She is an SME in market access, rare disease and biosimilars.

Medicine 114
article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

Over the last 25 years, the headcount in the medicines manufacturing sector has fallen by 7,000 and since 2009 production volumes have fallen by nearly a third (29%), suggesting “faltering attractiveness” of the UK for manufacturing. Established trends are unfortunately firmly in the wrong direction.